Stock Spotlight

Stock Spotlight: Cochlear Limited (ASX:COH)

Stock Spotlight: Cochlear Limited (ASX:COH)

Key stats

$6.03B
Market cap
$95.00
Share price
-63.38%
1 year return
17.46
P/E ratio
4.32%
Dividend yield
0.51
Beta
$5.28
EPS
3.08
PEG ratio
Short interest
Healthcare
Industry

Source: EODHD. Data as of 24/04/26.

This week's Stock Spotlight is ASX-listed Cochlear Limited .

About Cochlear Limited.

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor and Baha implant; and accessories, such as wireless devices and Nucleus water-safe accessories. The company was founded in 1981 and is headquartered in Sydney, Australia.

Source: EODHD

Price Performance

Growth Potential

  • Share price & trading multiples have materially de-rated post the latest earnings downgrade and are now trading on undemanding metrics subject to no further earnings downgrades.
  • The key concern for investors from the update was the slowdown in sales in COH’s key adult & seniors’ segment in developed markets. Management believes COH’s sales correlate more closely with consumer sentiment – which is at an all-time low in the U.S. – than previously seen. This raises questions about the defensive nature of COH’s sales, given that consumers and hospitals are “deprioritizing” Cochlear Implant (CI) surgeries.
  • Management believes they can return to delivering CI volumes growth of +10% p.a. and is still targeting NPAT margin of 18% over the medium term.
  • Market leading positions globally.
  • Best in class R&D program (significant dollar amount) leading to continual development of new products and upgrades to existing suite of products.
  • New product launches – the launch of Nucleus Nexa is in line with expectations
  • Solid balance sheet position.

Key Risks

  • Product recall.
  • R&D program fails to deliver innovative products.
  • Increase in competitive pressures.
  • Change in government reimbursement policy.
  • Adverse movements in AUD/USD.
  • Emerging market does not recoup – significant downside to earnings.

Frequently asked questions

This article is general information only and does not take into account your objectives, financial situation or needs. It is not a recommendation to buy or sell any security. Past performance is not a reliable indicator of future performance. Consider seeking financial, legal and taxation advice before investing.

Newsletter

Get our insights in your inbox

Join the Sharewise newsletter for new market insights and stock spotlights, plus invites to company webinars and Stocks and Sips evenings.

More articles

All news →

Want more than one article's worth?

Sharewise clients get ongoing research, Advisor access and execution across ASX, US and global markets.

Explore our services →